IXA 2025 - Mobis

P1.01 Improving pig red blood cell transfusion safety with anti-CD154 co-administration in nonhuman primates

Prof. Hee Jung Kang, Korea

P1.02 Systemic inflammatory biomarkers versus graft specific hTBM in monitoring xenograft status

Ms. Farzana Rahman, United States

P1.03 Xenotransplantation hope: Flying pigs and the people who make it happen

Dr. Anja MB Jensen, Denmark

P1.04 Brain-dead donors in xenotransplantation research: Global trends and legal-ethical challenges in Korea

Dr. Hyeonji Jeon, Korea

P1.05 Production and characterization of transgenic pigs for xenotransfusion by knock-in of human CD46 and TBM or CD59 and CD47 genes at the GGTA1 exon4 locus

Mr. Jun-Hyeong Kim, Korea

P1.06 Blood-derived endothelial progenitor cells enable non-terminal verification of endothelial-specific transgene expression in GTKO/MCP/TBM pigs

Dr. Sang Eun Kim, Korea

P1.07 Generation of 10 gene pigs in one step with combination of CRISPR/CAS9 and 2A self-cleaving multigene expression system

Dr. KASINATH V KURAVI, United States

P1.08 Interspecies chimerism with human expanded potential stem cells in porcine embryos

Dr. Mayuko Kurome, Germany

P1.09 Site-specific integration of HO1 and CD47 at the CMAH locus in GTKO pigs for immunomodulation in xenotransplantation

Dr. Keon B Oh, Korea

P1.10 Expression of a retroviral immunosuppressive protein on the xenotransplant – A way to reduce pharmacological immunosuppression?

Joachim Denner, Germany

P1.11 LEA29Y expression affects myocardial scar formation after ischemia/reperfusion in pigs

Heinke Heymer, Germany

P1.12 Bispecific anti-CD40LxCD28 antibody prevents mouse xenogeneic GVHD

Ms. Siwon Hwang, Korea

P1.13 Dosing of pegcetacoplan with plasmapheresis for treatment of xenoantibody mediated rejection

Dr. Karen Khalil, United States

P1.14 Immunomodulatory ability of porcine peripheral blood-derived mesenchymal stem cells in xenotransplantation

Ji Woo Shin, Korea

P1.15 Impact of the high baseline anti-A/B antibody titer on the clinical outcomes in ABO-incompatible living donor liver transplantation

Prof. Jai Young Cho, Korea

P1.16 Suppressive effect of mycophenolic acid on the cytotoxicity of human macrophages against swine endothelial cells

Dr. Yusuke Yanagino, Japan

P1.17 Attitudes toward pig islet xenotransplantation for type 1 diabetes: A scoping review

Dr. Daniel Hurst, United States

P1.18 Optimizing aCD154-free immunosuppression and monitoring in QKO pig-to-monkey islet xenotransplantation

Prof. Beom Seok KIM, Korea

P1.19 Islet recovery and functionality retained after 24-hour static cold storage of neonatal porcine pancreas in University of Wisconsin solution

Mr. Ivan J. Ma, Canada

P1.20 Nanodelivery of IL 33 locally amplifies the ILC2 and Treg to protect the graft in islet transplantation

Juan OIFRPA Chen, People's Republic of China

P1.21 Supply chain flexibility for a porcine beta cell replacement therapy to treat type 1 diabetes

Dr. Yanick Fanton, Belgium

P1.23 Targeting the activity of beta cells by membrane surface redox regulation for islet transplantation

Dr. Jianmin Wu, People's Republic of China

P1.24 Establishing a xenotransplantation program in Armenia to enhance surgical training and explore the role of polyamines in liver graft rejection

Dr. HAYK Harutyunyan, Armenia

P1.25 Unravelling the dynamic process of NPI maturation at the single cell transcriptome level

Prof. Elisabeth Kemter, Germany

P1.26 Genetic diversity and population structure of GTKO-engineered Xeno pigs across generations based on SNP analysis

Dr. W Lee, Korea

P1.27 Preliminary results of obtaining designated pathogen-free pigs in a pig facility for xenotransplantation in Brazil

Dr. Ernesto Goulart, Brazil

P1.28 Comparison of morphological quality of fetal fibroblasts fsed in nuclear transfer for swine embryo production for xenotransplantation

Dr. Ernesto Goulart, Brazil

P1.29 A rational design method for tissue dissociation enzyme optimization (RDMTDE method)

Robert C McCarthy, United States

P1.31 An ancillary material supplier's perspective on ISO 20399:2022

Mr. Andrew G Breite, United States

P1.32 Quality systems driving innovation: Implementing QMS, QA, and QC for genetically modified pigs in xenotransplantation

Mrs. Ludmila Garcia, Brazil

P1.33 Mapping the evolution of solid organ xenotransplantation research: a systematic review

Dr. Ivana Juric, France

P1.34 Fabrication strategy of parathyroid organoids and their applicability for non-clinical primate transplantation

Dr. Sun Ae Hwang, Korea